Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon

Colorectal Cancer Clinical Trial

Official title:

Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00085163
• Other study ID #: EORTC-40023
• Secondary ID: EORTC-40023PETAC
• Status: Completed
• Phase: Phase 3
• First received: June 10, 2004
• Last updated: October 19, 2015
• Start date: March 2004

Study information

• Verified date: October 2015
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether fluorouracil and leucovorin are more effective with or without celecoxib in treating resected stage III adenocarcinoma (cancer) of the colon.

PURPOSE: This randomized phase III trial is studying celecoxib, fluorouracil, and leucovorin to see how well they work compared to fluorouracil and leucovorin in treating patients who have undergone surgery for stage III colon cancer.

Description:

OBJECTIVES:

Primary

• Compare disease-free survival of patients with curatively resected stage III adenocarcinoma of the colon treated with adjuvant fluorouracil and leucovorin calcium with or without celecoxib.

Secondary

• Compare the overall survival, the occurrence of new primary colon cancer, and the development of new polyps in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to ≥ 4 tumor-positive lymph nodes (yes vs no), form of adjuvant chemotherapy (infusional vs bolus), low-dose aspirin for cardiovascular prophylaxis (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive fluorouracil and leucovorin calcium IV for up to 6 courses in the absence of disease recurrence or unacceptable toxicity. Patients also receive oral celecoxib twice daily.

• Arm II: Patients receive oral placebo twice daily and fluorouracil and leucovorin calcium as in arm I.

In both arms, treatment with celecoxib or placebo continues for 3 years in the absence of disease recurrence or unacceptable toxicity.

Patients are followed annually for 2 years.

PROJECTED ACCRUAL: A total of 1,450 patients (725 per treatment arm) will be accrued for this study within 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. primary completion date: November 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the colon

• 15 cm above anal verge

• Stage III disease (any pT, N1-2, M0)

• No rectal cancer

• Must have undergone curative radical resection (R0 resection) within the past 6 weeks

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• WHO 0-1

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

Hepatic

• AST = 5 times upper limit of normal (ULN)

• Bilirubin = 1.5 times ULN

Renal

• Creatinine = 1.5 times ULN

Cardiovascular

• None of the following conditions within the past 6 months:

• Myocardial infarction

• Unstable angina

• Symptomatic congestive heart failure

• Serious uncontrolled cardiac arrhythmia

• Cerebrovascular accident or transient ischemic attack

• Deep vein thrombosis

• Other significant thromboembolic event

Pulmonary

• No pulmonary embolism within the past 6 months

Gastrointestinal

• No active gastric or duodenal ulceration within the past year

• No gastrointestinal bleeding within the past year

• No partial or complete bowel obstruction

• No known chronic malabsorption

• No active inflammatory bowel disease or chronic diarrhea (more than 4 stools/day)

Other

• Not pregnant or nursing

• Fertile patients must use effective contraception

• HIV negative

• No AIDS-related illness

• No prior hypersensitivity to fluorouracil, leucovorin calcium, celecoxib, other COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides

• No other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation, study drug administration, or study results interpretation

• No psychological, familial, sociological, or geographical condition that would preclude study compliance

• No concurrent active infection

• No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No concurrent sargramostim (GM-CSF) or molgramostim

Chemotherapy

• Not specified

Endocrine therapy

• No more than 4 weeks of concurrent orally/nasally inhaled steroids over a 6-month period

• Concurrent mometasone (or fluticasone) allowed if patients require = 4 weeks of inhaled steroid therapy

• At least 30 days since other prior steroids

• No concurrent hormonal therapy

Radiotherapy

• No concurrent radiotherapy

Surgery

• See Disease Characteristics

• No prior total colectomy or other major surgery that would result in substantial alteration in transit to absorption of oral medication

Other

• More than 30 days since prior investigational medication

• No prior systemic anticancer treatment for colon cancer

• No concurrent prophylactic fluconazole

• No concurrent lithium

• No concurrent chronic* use of full dose aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or cyclo-oxygenase-2 (COX-2) inhibitors

• Aspirin at cardioprotective doses (i.e., 80 mg daily or equivalent) allowed

• No concurrent participation in any other clinical study

• No other concurrent experimental agents (e.g., other COX-2 inhibitors, matrix metalloproteinase inhibitors, inhibitors of the vascular endothelial growth factor/Flk-1 pathway, or inhibitors of the epidermal growth factor receptor pathway) NOTE: *Chronic use is defined as a frequency of 7 consecutive days (1 week) for more than 3 weeks/year or more than 21 days throughout the year

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer

Intervention

Drug:
• celecoxib

• fluorouracil

• leucovorin calcium

Procedure:
• adjuvant therapy

Locations

Country	Name	City	State
Austria	Karl-Franzens-University Graz	Graz
Austria	Innsbruck Universitaetsklinik	Innsbruck
Austria	Krankenhaus der Elisabethinen	Linz
Austria	St. Vincent's Hospital	Linz Donau
Austria	Landeskrankenanstalten - Salzburg	Salzburg
Austria	Allgemeines Krankenhaus der Stadt Wien	Vienna
Austria	Allgemeines Krankenhaus	Wiener Neustadt
Belgium	Ziekenhuis Netwerk Antwerpen Middelheim	Antwerpen
Belgium	Hopital Universitaire Erasme	Brussels
Belgium	Universitair Ziekenhuis Antwerpen	Edegem
Belgium	Hopital de Jolimont	Haine Saint Paul
Belgium	CHU Liege - Domaine Universitaire du Sart Tilman	Liege
Belgium	St. Elizabeth Ziekenhuis	Turnhout
Netherlands	Medisch Centrum Haaglanden	's-Gravenhage
Netherlands	Jeroen Bosch Ziekenhuis	's-Hertogenbosch
Netherlands	Academisch Medisch Centrum at University of Amsterdam	Amsterdam
Netherlands	Onze Lieve Vrouwe Gasthuis	Amsterdam
Netherlands	Gelre Ziekenhuizen - Lokatie Lukas	Apeldoorn
Netherlands	Rijnstate Hospital	Arnhem
Netherlands	Ziekenhuis Lievensberg	Bergen-op-Zoom
Netherlands	Deventer Ziekenhuisen	Deventer
Netherlands	Catharina Ziekenhuis	Eindhoven
Netherlands	Medisch Spectrum Twente	Enschede
Netherlands	University Medical Center Groningen	Groningen
Netherlands	Ziekenhuis St Jansdal	Harderwijk
Netherlands	Leiden University Medical Center	Leiden
Netherlands	Sint Antonius Ziekenhuis	Nieuwegein
Netherlands	Nijmegen Cancer Center at Radboud University Medical Center	Nijmegen
Netherlands	Waterlandziekenhuis	Purmerend
Netherlands	Daniel Den Hoed Cancer Center at Erasmus Medical Center	Rotterdam
Netherlands	Erasmus MC - Sophia Children's Hospital	Rotterdam
Netherlands	Ikazia Ziekenhuis	Rotterdam
Netherlands	Schieland Ziekenhuis	Schiedam
Netherlands	Ziekenhuis de Honte	Terneuzen
Netherlands	Streekziekenhuis Koningin Beatrix	Winterswyk
Netherlands	Isala Klinieken - locatie Weezenlanden	Zwolle

Sponsors (14)

Lead Sponsor

Collaborator

European Organisation for Research and Treatment of Cancer - EORTC

Arbeitsgemeinschaft fur Internistische Onkologie, Dutch Colorectal Cancer Group (DCCG), EFCR - Egyptian foundation for Cancer Research, EORTC GI Group (EORTC 40023), Federation Francophone de Cancerologie Digestive, GCCD-APIO - Grupo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação, GOCCI - Gruppo Oncologico Chirurgico Cooperativo Italiano, GOIRC - Gruppo Oncologico Italiano di Ricerca Clinica, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Oncológica, Onkologie, SG - Scandinavian Group, TTD - Grupo Español para el Tratamiento de Tumores Digestivos

Countries where clinical trial is conducted

Austria,  Belgium,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter			No
Secondary	Overall survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter			No
Secondary	Time occurrence of new primary colon cancer and new polyps as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter			No
Secondary	Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter			Yes